For context, existing FDA-approved medications for alcohol use disorder, like naltrexone and acamprosate, typically show reductions in the range of 15 to 25%
It assists in the breakdown of glycogen to free up stored glucose for energy
Importantly, these medications are not generally recommended in patients with severe gastrointestinal disease, including severe gastroparesis, which may be relevant when considering their use in individuals with Crohn's disease
Guarantee: ProHealth materials indicate a 100-day, 100 percent satisfaction guarantee
Notably, there was a substantial reduction in ABCG2 abundance (from 78 to 44%) and severe functional defects observed in the intestines of these mice [52]
Sodium-glucose transport protein 2 (SGLT2) inhibitors Primary mechanism(s) of action Reduce reabsorption of glucose in the kidneys (renal tubules) by inhibiting sodium-glucose transport protein 2 (SGLT2)